With your own knowledge and the help of the following document:

Document 1 (Title: Adverse Effects of Topical Nasal Decongestant Overuse): Topical nasal decongestants, including oxymetazoline, phenylephrine, and xylometazoline, provide rapid, effective relief of nasal congestion through their alpha-adrenergic agonist properties causing vasoconstriction of the nasal mucosal blood vessels. While these agents demonstrate excellent efficacy for short-term management of nasal congestion from various etiologies, their use beyond 3-5 consecutive days can lead to a paradoxical condition known as rhinitis medicamentosa. This iatrogenic form of rhinitis develops through a complex pathophysiological process involving both neurological and vascular mechanisms. The primary mechanism involves down-regulation and desensitization of alpha-adrenergic receptors in the nasal mucosa due to continuous exposure to exogenous sympathomimetics. This receptor desensitization leads to rebound vasodilation when the medication effect wanes, producing congestion that exceeds the pre-treatment state. Accompanying histopathological changes include chronic inflammation, epithelial metaplasia, and mucosal edema, which further compound the congestive symptoms. The cardinal clinical manifestation is persistent nasal congestion, most pronounced immediately after the decongestant effect subsides, creating a cycle of increasingly frequent administration. Unlike allergic rhinitis, sneezing and rhinorrhea are typically absent or minimal. The condition rarely progresses to permanent alteration of nasal architecture or irreversible olfactory dysfunction, though prolonged cases may temporarily impact smell through mechanical obstruction. Similarly, epistaxis occurs in only a minority of cases, typically related to mucosal dryness and microtrauma from the applicator. Management focuses primarily on discontinuation of the offending agent, often requiring a tapering schedule and temporary use of intranasal corticosteroids to mitigate withdrawal symptoms.
Document 2 (Title: Coagulation Defects in Young Women with Menorrhagia): Menorrhagia, defined as excessive menstrual bleeding lasting more than 7 days or exceeding 80 mL per cycle, affects approximately 10-30% of women of reproductive age, with a significant proportion attributable to underlying bleeding disorders. When persistent since menarche and accompanied by other mucocutaneous bleeding manifestations, inherited coagulation disorders warrant particular consideration. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects approximately 1% of the general population and accounts for up to 20% of unexplained menorrhagia cases in otherwise healthy women. VWD results from quantitative or qualitative deficiencies in von Willebrand factor (VWF), a large multimeric glycoprotein that mediates platelet adhesion to subendothelial collagen and serves as a carrier for factor VIII. This autosomal inheritance pattern leads to equal sex distribution, contrasting with the X-linked recessive inheritance of hemophilia A, which primarily affects males. Laboratory evaluation of VWD typically reveals prolonged activated partial thromboplastin time (aPTT) due to secondary factor VIII deficiency, while prothrombin time (PT) and platelet count remain normal. Patients typically present with mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, and particularly menorrhagia in women. Family history often reveals similar bleeding tendencies in first-degree relatives of both sexes, contrasting with the maternal uncle pattern in hemophilia A or the prothrombotic tendencies in conditions like protein C deficiency or antiphospholipid syndrome.
Document 3 (Title: Gastric Restrictive Procedures): 1. Vertical-Banded Gastroplasty (CPT code 43842) Vertical-banded gastroplasty was formerly one of the most common gastric restrictive procedures performed in the United States but has now been replaced by other restrictive procedures due to high rates of revisions and reoperations. In this procedure, the stomach is segmented along its vertical axis. To create a durable reinforced and rate-limiting stoma at the distal end of the pouch, a plug of stomach is removed, and a propylene collar is placed through this hole and then stapled to itself. Because the normal flow of food is preserved, metabolic complications are uncommon. Complications include esophageal reflux, dilation, or obstruction of the stoma, with the latter two requiring reoperation. Dilation of the stoma is a common reason for weight regain. Vertical-banded gastroplasty may be performed using an open or laparoscopic approach. 2. Adjustable Gastric Banding (CPT code 43770) Adjustable gastric banding involves placing a gastric band around the exterior of the stomach. The band is attached to a reservoir that is implanted subcutaneously in the rectus sheath. Injecting the reservoir with saline will alter the diameter of the gastric band; therefore, the rate-limiting stoma in the stomach can be progressively narrowed to induce greater weight loss, or expanded if complications develop. Because the stomach is not entered, the surgery and any revisions, if necessary, are relatively simple. Complications include slippage of the external band or band erosion through the gastric wall. Currently, two such devices are approved by the US Food and Drug Administration (FDA) for marketing in the United States. The first to receive FDA approval was the LapBand (Apollo Endosurgery). The labeled indications for Lap Band devices are as follows: "The Lap-Band system is indicated for use in weight reduction for severely obese patients with a body mass index (BMI) of at least 40 or a BMI of at least 35 with one or more severe comorbid conditions, or those who are 100 lbs or more over their estimated ideal weight according to the 1983 Metropolitan Life Insurance Tables (use the midpoint for medium frame). It is indicated for use only in severely obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise and behavior modification programs. Patients who elect to have this surgery must make the commitment to accept significant changes in their eating habits for the rest of their lives." In 2011, FDA-labelled indications for the LAP-BAND were expanded to include patients with a BMI from 30 to 34 with at least 1 obesity-related comorbid condition. The second adjustable gastric banding device was approved by the FDA through the Premarket Approval (PMA) process in September 2007, the REALIZE model (Ethicon Endosurgery, Cincinnati, OH). Labeled indications for this device are as listed below: "The [REALIZE] device is indicated for weight reduction for morbidly obese patients and is indicated for individuals with a BMI of at least 40 kg/m2, or a BMI of at least 35 kg/m2 with one or more comorbid conditions. The band is indicated for use only in morbidly obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise, and behavior modification programs." 3. Sleeve gastrectomy (CPT code 43775) A sleeve gastrectomy is an alternative approach to gastrectomy that can be performed on its own, or in combination with malabsorptive procedures (most commonly biliopancreatic diversion with duodenal switch). In this procedure, the greater curvature of the stomach is resected from the angle of His to the distal antrum, resulting in a stomach remnant shaped like a tube or sleeve. The pyloric sphincter is preserved, resulting in a more physiologic transit of food from the stomach to the duodenum, and avoiding the dumping syndrome (overly rapid transport of food through stomach into intestines) that is seen with distal gastrectomy. This procedure can be done by the open or laparoscopic technique. Some surgeons have proposed this as the first in a two-stage procedure for very high-risk patients. Weight loss following sleeve gastrectomy may improve a patient’s overall medical status, and thus reduce the risk of a subsequent more extensive malabsorptive procedure, such as biliopancreatic diversion.

Answer the following multiple-choice question.
Question: A 35-year-old male presents to his primary care physician with complaints of seasonal allergies. He has been using intranasal vasoconstrictors several times per day for several weeks. What is a likely sequela of the chronic use of topical nasal decongestants?
Options:
A. Epistaxis
B. Permanent loss of smell
C. Persistent nasal crusting
D. Persistent congestion

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ← if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.